Ambrosia Bio
Enzyme-Based Bioprocess Technology for Low-Calorie Sugar Alternatives
Company Overview
Snapshot
Founded in September 2020 by Ziv Zwighaft, Ambrosia Bio operates with 1–10 employees. The company has secured $1.52 million across 8 funding rounds from 2 investors. In March 2022, Ambrosia Bio received funding from Brinc.
Business overview
Ambrosia Bio develops disruptive enzyme technology to convert industrial sugars into minimal-calorie rare sugars like Allulose. The company's B2B model provides tailored engineering solutions to sugar and Food & Beverages manufacturers, enabling them to meet consumer demand for sugar reduction without compromising taste. Ambrosia Bio operates within the Agriculture & Food Technologies sector, specifically focusing on Novel Food & Ingredients.
Strategic signal
In June 2022, Ambrosia Bio was recognized as a winner in an industrial biotech start-up contest by TWB. This validation highlights the company's innovative enzyme technology and its potential to significantly impact the food industry by enabling the production of low-calorie sugar alternatives, signaling strong market relevance and technological advancement to investors.
Log in to access full profile ›Company Intelligence Q&A
- When was Ambrosia Bio founded?
- Ambrosia Bio was founded in September 2020 by Ziv Zwighaft.
- What is Ambrosia Bio's core technology?
- Ambrosia Bio's core technology is an enzyme-based bioprocess platform designed to convert industrial sugars into low-calorie rare sugars such as Allulose.
- What was a significant recent recognition for Ambrosia Bio?
- In June 2022, Ambrosia Bio was announced as a winner in an industrial biotech start-up contest organized by TWB.
- Has Ambrosia Bio received any grant funding?
- Yes, in August 2021, Ambrosia Bio received a grant from the Israel Innovation Authority. Additionally, in June 2021, the company received a grant from the EIT Food Accelerator Network.